Change of Adviser

RNS Number : 9917S

N4 Pharma PLC

15 July 2020

 

15 July 2020

N4 Pharma plc

("N4 Pharma" or the "Company")

Change of Adviser

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce the appointment of SP Angel Corporate Finance LLP as the Company's Nominated Adviser and Joint Broker, with immediate effect.

Management Change

The Company also announces that Luke Cairns, previously a Non-Executive Director of the Company, has been appointed to an Executive Director position.  Luke will be overseeing the Company's finance and investor relations activities, thereby allowing Nigel Theobald, Chief Executive Officer, more time to focus on driving the Company's development programmes and potential commercial collaborations. 

Enquiries:

N4 Pharma plc
Nigel Theobald, CEO	Via Scott PR
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: [phone]
Joint Broker
Andy Thacker
Scott PR
Georgia Smith	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

APPRIMITMTJBBMM